Product Description
Dexlansoprazole is used to treat the symptoms of gastroesophageal reflux disease (GERD; a condition in which backward flow of acid from the stomach causes heartburn and possible injury of the esophagus [tube between the throat and stomach]) in adults and children 12 years of age and older. It is also used to treat esophagitis (swelling that may damage tissues of the esophagus) in adults and children 12 years of age and older. Dexlansoprazole is used for the maintenance treatment of esophagitis and healing in adults and children 12 years of age and older. Dexlansoprazole is in a class of medications called proton pump inhibitors. It works by decreasing the amount of acid made in the stomach. (Sourced from: https://medlineplus.gov/druginfo/meds/a609017.html)
Mechanisms of Action: Proton Pump Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Bangladesh | Bosnia | Brazil | Canada | Colombia | Dominican Republic | Ecuador | Egypt | Germany | Hong Kong | India | Ireland | Israel | Italy | Jordan | Korea | Lebanon | Lithuania | Malaysia | Mexico | Peru | Philippines | Poland | Portugal | Russia | Saudi Arabia | Serbia | Singapore | Slovenia | South Africa | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United States | Uruguay | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China, Poland
Active Clinical Trial Count: 7
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Esophagitis|Gastroesophageal Reflux
Phase 2: Bile Reflux|Duodenal Ulcer|Stomach Ulcer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| TAK-390MR_205 | P2 |
Recruiting |
Esophagitis |
2027-10-31 |
2025-05-02 |
Treatments |
|
| TAK-390MR_204 | P2 |
Recruiting |
Bile Reflux |
2027-10-31 |
2025-05-02 |
Treatments |
|
| CTR20160226 | P3 |
Recruiting |
Esophagitis |
None |
2025-04-29 |
Patient Enrollment|Treatments|Trial Status |
|
| CTR20160225 | P3 |
Recruiting |
Gastroesophageal Reflux |
None |
2025-04-29 |
Patient Enrollment|Treatments|Trial Status |
|
| CTR20200086 | P1 |
Active, not recruiting |
Duodenal Ulcer |
None |
2025-04-29 |
Treatments|Trial Status |
|
| CTR20210534 | P2 |
Recruiting |
Duodenal Ulcer|Stomach Ulcer |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
| CTR20181099 | P1 |
Recruiting |
Duodenal Ulcer |
None |
2025-04-29 |
Patient Enrollment|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
12/21/2023 |
News Article |
Proton Pump Inhibitors Market Size to Surpass US$ 5.64 billion by 2031 - Growth Plus Reports |
|
09/27/2023 |
News Article |
Gerd and Nerd Treatment Market Overview, Size, Share and Forecast 2031 |
|
09/26/2023 |
News Article |
Gastroesophageal Reflux Drugs Market Latest ReportSize, Share and Growth Forecast by 2023 to 2030 |
|
09/18/2023 |
News Article |
Proton Pump Inhibitors Market Drivers, Challenges, Impact on Growth, Demand and Forecasts in [2023-2029] |